All In Biotech

Drug Trial Radar · NCT01243411

A Study of AA4500 in Men With Peyronie's Disease

A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

348

Actual

Start

Nov 2010

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. After up to four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 168 (± 7 days) and 252 (± 7 days) (nominal weeks 24 and 36). After the final injection of each treatment cycle, the investigator will model the plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15° after the first, second, or third cycle of injections or if the investigator determines further treatment is not clinically indicated (eg, adverse events; allergic reaction), subsequent treatment cycles will not be administered. Approximately 300 subjects will be enrolled.

Conditions

  • Peyronie's Disease

Interventions

  • AA4500Biological

    2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Penile CurvatureTime frame: Baseline and Week 36
  2. Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)Time frame: Baseline and Week 36

Locations

39 sites in 9 countries. Site status is shown where the registry gives one.

  • Urology Associates Medical Group

    Burbank, California

  • Connecticut Clinical Research Center, LLC

    Middlebury, Connecticut

  • The Urology Center, P.C.

    New Haven, Connecticut

  • South Florida Medical Research

    Aventura, Florida

  • Urology Specialists, S.C.

    Chicago, Illinois

  • Northeast Indiana Research, LLC

    Fort Wayne, Indiana

  • Metropolitan Urology, P.S.C.

    Jeffersonville, Indiana

  • Maimonides Medical Center, Division of Urology

    Brooklyn, New York

  • University Urology Associates

    New York, New York

  • Tristate Urologic Services PSC, Inc./ dba TUG Research

    Cincinnati, Ohio

  • Urologic Consultants of SE PA

    Bala-Cynwyd, Pennsylvania

  • Urology of Virginia-Sentara Medical Group

    Norfolk, Virginia

  • Virginia Urology

    Richmond, Virginia

  • Aarhus Universitiy Hospital, Aalborg Sygehus

    Aalborg, Denmark

  • Frederiksberg Hospital

    Frederiksberg, Denmark

  • Frederikssunds Hospital

    Frederikssund, Denmark

  • Klinik for seksuelle dysfunktioner

    Gentofte Municipality, Denmark

  • Centre Hospitalier Edouar Herriot

    Lyon, France

  • Hopital Henri Gabrielle

    Saint-Genis-Laval, France

  • Universitatsklinikum Freiburg, Abteilung Urologie

    Freiburg im Breisgau, Germany

  • Private Practice of Urology/Andrology

    Hamburg, Germany

  • Uro-Onkologische Praxis Dr. von Keitz

    Marburg, Germany

  • Urologische Gemeinschaftspraxis Reutlingen

    Reutlingen, Germany

  • Universitatsklinikum Tubingen

    Tübingen, Germany

  • University of Naples "Federico II"

    Naples, Italy

  • Universitiy Tor Vergatat of Rome

    Rome, Italy

  • Waitemata Urology Research North Shore Hospital

    Takapuna, Auckland, New Zealand

  • Tauranga Urology Research Ltd.

    Tauranga, Bay of Plenty, New Zealand

  • Primorus Clinical Trials Ltd.

    Christchurch, Canterbury, New Zealand

  • CURT Medical Trials Trust Board Inc.

    Christchurch, Canterbury, New Zealand

  • Cardinal Points Research Ltd.

    Whangarei, Northland, New Zealand

  • Wellington Urology Associates

    Wellington South, Wellington Region, New Zealand

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital La Zarzuela

    Madrid, Spain

  • Specialistmottagningen i urologi

    Gothenburg, Sweden

  • Carlshamns Specialistklinik

    Karlshamn, Sweden

  • Akademiska Sjukhuse

    Uppsala, Sweden

  • St. Peter's Andrology Centre

    London, United Kingdom

  • Sunderland Royal Hospital

    Sunderland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.